dc.contributor.author | Desar, IME | |
dc.contributor.author | Ottevanger, PB | |
dc.contributor.author | Benson, C | |
dc.contributor.author | van der Graaf, WTA | |
dc.date.accessioned | 2017-12-19T14:25:30Z | |
dc.date.issued | 2018-02 | |
dc.identifier.citation | Critical reviews in oncology/hematology, 2018, 122 pp. 10 - 20 | |
dc.identifier.issn | 1040-8428 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/977 | |
dc.identifier.eissn | 1879-0461 | |
dc.identifier.doi | 10.1016/j.critrevonc.2017.12.009 | |
dc.description.abstract | Uterine sarcomas (US) are rare mesenchymal tumours of the uterus and are divided mainly into uterine leiomyosarcoma (uLMS), low grade endometrial stromal sarcoma (LG-ESS), high grade endometrial stromal sarcoma (HG-ESS), adenosarcomas and high grade undifferentiated sarcoma (HGUS). US are often high-grade tumours with a high local recurrence rate and metastatic risk. We here discuss the current standard of care and knowledge of systemic therapy for adult uterine sarcomas, in particular uLMS, LG-ESS, HG-ESS and HGUS, in both the adjuvant as well as the metastatic setting. | |
dc.format | Print-Electronic | |
dc.format.extent | 10 - 20 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Sarcoma, Endometrial Stromal | |
dc.subject | Leiomyosarcoma | |
dc.subject | Sarcoma | |
dc.subject | Uterine Neoplasms | |
dc.subject | Endometrial Neoplasms | |
dc.subject | Chemotherapy, Adjuvant | |
dc.subject | Radiotherapy, Adjuvant | |
dc.subject | Adult | |
dc.subject | Female | |
dc.title | Systemic treatment in adult uterine sarcomas. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-12-12 | |
rioxxterms.versionofrecord | 10.1016/j.critrevonc.2017.12.009 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2018-02 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Critical reviews in oncology/hematology | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.publication-status | Published | |
pubs.volume | 122 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Clinical and Translational Sarcoma | en_US |
dc.contributor.icrauthor | van der Graaf, Wilhelmina | |